Related Experiment Video
Updated: Aug 9, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Targeted approaches for the management of metastatic prostate cancer
Kathleen W Beekman1, Maha Hussain
1Genitourinary Oncology Service, Department of Medicine, Division of Hematology-Oncology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, C-409/0843 MIB, Ann Arbor, MI, 48109-0843, USA. katew@umich.edu
Abstract:
Huggins and Hodges described the first systemic targeted therapy for prostate cancer in 1941 with their report on the effects of androgen ablation in men with metastatic disease. Since that time, researchers have identified multiple additional "targets" that may be important in prostate cancer tumorigenesis. These areas include continued emphasis on the androgen receptor in the androgen-independent state, parallel growth pathways such as AKT and HER2 that may act in conjunction or independently of the androgen receptor, the supporting environment that allows for the development of metastatic disease, and standard cytotoxic targets, such as the microtubule. This review is intended to highlight these potential targets and several of the agents that are under development in the treatment of prostate cancer.
Insights
This review highlights new targets for prostate cancer treatment beyond androgen ablation. It discusses agents targeting androgen receptor, growth pathways, metastasis, and microtubules in development.
Area of Science:
- Oncology
- Urology
Background:
- The first targeted therapy for prostate cancer involved androgen ablation in 1941.
- Since then, numerous other targets in prostate cancer have been identified.
Purpose of the Study:
- To review potential targets for prostate cancer treatment.
- To highlight agents under development for prostate cancer therapy.
Main Methods:
- Literature review of prostate cancer research.
- Identification of key molecular targets and therapeutic agents.
Main Results:
- Androgen receptor remains a key target, even in androgen-independent states.
- Parallel growth pathways (AKT, HER2) and the tumor microenvironment are crucial.
- Microtubules represent a standard cytotoxic target.
Conclusions:
- Multiple novel targets are being explored for prostate cancer treatment.
- Several new therapeutic agents targeting these pathways are in development.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...